More Real Than Real

A woman in her fifties, being treated for cancer at New York University, was asked afterwards to describe what had happened to her during her psilocybin session. She said: “It’s the first time I ever really felt like I was part of the world instead of separate from it.” Asked to say more, she couldn’t. “It’s really hard to describe,” she said. “You just know.”

I know that sentence. I’ve said nearly the same thing myself, about my own experiences with psilocybin, which I wrote about in Let It Happen. When I’m in that state, it is absolutely axiomatic that everything is unified. It isn’t a question, or something you reason yourself into. It’s just known, and inhabited. The plant always feels like a response. I believe these experiences heal. And I believe they put you back into alignment with the real reality, that you learn through them you have no better guide than your own instinct. The veil lifts.

This site is named for a sentence by Terence McKenna, who believed all of that and said it more vividly than anyone. In a lecture in Seattle in 1994, he described a sick society producing “antibodies,” and he listed them: “surrealism, body piercing, psychedelic drug use, sexual permissiveness, jazz, experimental dance, rave culture, tattooing.” Psychedelics were on the list from the start. It has taken this project a long time to come back to them.

So here is the question I’m bringing through The Edge’s door, where the strongest evidence goes first and the losses get reported. Not do psychedelics do anything? They do. The question is whether the thing that woman felt, and that I’ve felt, is the point. Is the experience the medicine? Or is it a beautiful side effect of something happening in the brain that would heal you anyway?

I.The Phenomenon

Start with something older than us.

The mushrooms that make psilocybin have been making it for a very long time. Geneticists who traced the family tree of Psilocybe in 2024 put its origin at roughly sixty-five million years ago, around the time the dinosaurs died. Stranger still, the handful of genes that build the molecule turn up in mushrooms that aren’t closely related at all. They seem to have jumped between species, passed sideways from one fungus to another, the way bacteria trade genes. Nobody knows for certain why a mushroom would make psilocybin. One idea is that it’s a defence, a chemical that makes the mushroom unpleasant to the insects and slugs that would eat it.

Whatever the reason, the molecule the mushroom makes happens to be shaped very much like serotonin, one of the chemicals our own nervous systems use to signal. When we eat it, it fits a lock in the human brain that evolved for entirely different purposes. A fungus, guarding itself against slugs, made a key to a door in us. Everything else in this piece comes through that door.

What’s on the other side has been described for a long time, and the best description is still more than a century old. In 1902 the psychologist William James set out to find what mystical experiences had in common, across every religion and none. He settled on four marks.

The first is that they can’t be put into words. “The subject of it immediately says that it defies expression, that no adequate report of its contents can be given in words.” It’s really hard to describe. You just know.

The second is that they feel like knowledge, not emotion. “Although so similar to states of feeling,” James wrote, “mystical states seem to those who experience them to be also states of knowledge. They are states of insight into depths of truth unplumbed by the discursive intellect.” Part of the world instead of separate from it.

The third is that they pass: “half an hour, or at most an hour or two, seems to be the limit beyond which they fade into the light of common day.” And the fourth is that they happen to you, “as if he were grasped and held by a superior power.”

James got there partly by inhaling nitrous oxide, and it left him with a conviction he never shook: “our normal waking consciousness, rational consciousness as we call it, is but one special type of consciousness, whilst all about it, parted from it by the filmiest of screens, there lie potential forms of consciousness entirely different.”

People who take psilocybin describe all four marks, and researchers now measure them with questionnaires that ask about unity, sacredness, joy, the falling away of time and space, and the impossibility of saying any of it. The numbers from the big surveys are striking, though they come from people who chose to answer, often years later. About three-quarters of the people in one large survey, with psychedelics or without, ranked their experience among the five most meaningful of their lives. In another, of people who had encountered some kind of presence on the psychedelic DMT, 81 percent said it was more real than everyday consciousness.

But the reports aren’t only of revelation. People laugh, and people weep. In the first modern study at Johns Hopkins, session monitors noted far more joy, peace and crying in the psilocybin sessions than in the comparison sessions, and a footnote records humming, sighs and laughter. People feel their senses cross. One of the NYU patients said of the music: “I was the music. I was the drum, or the flute, or the violin, and I was really part of that.” People feel it in the body, as tingling or warmth or a rushing sensation. And people are afraid. In that same Hopkins study, nearly a third of the volunteers rated their fear at some point as strong or extreme.

That’s the phenomenon as it’s reported from the inside: ancient on the mushroom’s side, overwhelming on ours, and not yet explained.

II.What the Evidence Shows

Good Friday, 1962. On Good Friday, 20 April 1962, twenty divinity students gathered in Marsh Chapel at Boston University for the Good Friday service. A Harvard doctoral student named Walter Pahnke had paired them up and randomly given one of each pair psilocybin. The other got nicotinic acid, a vitamin that makes your skin flush and tingle, so they’d think they’d had something too.

It didn’t fool anyone for long. The flush faded, and by the end of the day every student knew which group he was in. That was the first sign of a problem the field still hasn’t solved.

The story has a second half. A quarter-century later, a researcher named Rick Doblin tracked the men down and interviewed sixteen of them. The ones who’d had psilocybin still described that morning as one of the high points of their spiritual lives, and they rated it even more highly than they had at six months. Most of the others “could barely remember even a few details of the service.” But Doblin also found what Pahnke had left out. One of the psilocybin subjects had walked out of the chapel, “possibly intending to follow the exhortation” of the sermon. There was a struggle, and he was given an injection of Thorazine, an antipsychotic. Pahnke’s thesis underreported it. Several of the others had been badly frightened. The most famous experiment in the history of the subject had quietly buried its worst moment.

Within a few years, the research was over. Harvard dismissed Richard Alpert in 1963, and Timothy Leary’s contract ran out. Psilocybin was outlawed, and in 1970 it was placed in Schedule I, the category for drugs with no accepted medical use. For a generation, almost no one studied it.

Two brothers. The road back runs, of all places, through Terence McKenna’s family. In 1971 Terence and his younger brother Dennis went into the Colombian Amazon and tried something they called “the Experiment,” following instructions Dennis now calls “mostly nonsense.” Terence came out of the jungle a bard. Dennis went another way. “Rather than rejecting science outright,” he said later, “I determined that I really should learn how to ‘do’ science before rejecting it.” He earned a doctorate in botany, studied the chemistry of Amazonian plant medicines, and in 1993 helped found the Heffter Research Institute, which helped fund the cancer trials described below. Same family, same night in the jungle, two roads out of it: one into the culture, one into the laboratory.

The living room. In 2006 a team at Johns Hopkins led by the psychopharmacologist Roland Griffiths published the study that restarted the field. They didn’t run it in a lab. One reporter described the setting as “a living room appointed with a comfortable couch, headphones and other spiritual journey aids.” Thirty-six healthy adults, none of whom had taken a psychedelic before, lay on that couch with two trained guides beside them. On one day they were given a high dose of psilocybin; on another, methylphenidate, the drug in Ritalin. Neither they nor the guides were told which was which.

Sixty-one percent had what the questionnaires counted as a complete mystical experience. Two months later, about two-thirds of those asked rated it among the five most meaningful experiences of their lives, and their friends and family reported changes in how they lived. More than a year later, most still said so.

The same paper is frank about the cost, and so should we be. Nearly a third of the volunteers went through a period of strong or extreme fear. A smaller number had passing feelings of paranoia. “Under unmonitored conditions,” the authors wrote, “it is not difficult to imagine such effects escalating to panic and dangerous behavior.”

The dying. Then the researchers turned to people for whom fear wasn’t hypothetical. In 2016, trials at Hopkins and at NYU gave psilocybin to people with life-threatening cancer who were suffering from depression and anxiety. Both found large, fast reductions. At NYU, 83 percent of the psilocybin group met the bar for an antidepressant response seven weeks later, against 14 percent of those who’d had a placebo.

The numbers are only part of it. When NYU researchers interviewed patients afterwards, one described attending her own funeral during the session: “When I was at my funeral there was this tremendous sadness, just like mourning, collective mourning.” Another remembered that her two therapists “were right there.” Many people who had been living in dread of their own deaths came back less afraid. For a few years, it looked like the most important development in psychiatry in a generation.

The field grows up. Then the trials got bigger and more careful, and the numbers came down. This is the part of the story that most coverage leaves out, and it’s the part this section exists to tell.

In 2021, the New England Journal of Medicine published a trial comparing psilocybin with escitalopram, an ordinary antidepressant. On the trial’s main measure, psilocybin wasn’t significantly better. Several other measures leaned its way, but those hadn’t been corrected for how many comparisons were made.

The early trials had compared psilocybin with a waiting list or a weak placebo. When companies ran large trials against a proper placebo or a tiny dose, the advantage shrank. In two big trials whose results were announced this year, by the company and not yet peer-reviewed, psilocybin beat the comparison by a few points on a sixty-point depression scale. That’s real, and it passed the statistical tests comfortably. It is also a fraction of what the first trials suggested. Another 2026 trial missed its main goal altogether, and its authors called it “an inconclusive trial.” A smaller one found a clear effect at eight days and none at a year.

And then there’s the problem Pahnke ran into in 1962. You can’t hide psilocybin. In the smaller 2026 trial, 94 to 100 percent of participants guessed whether they’d had it. A 2021 review found that of six psychedelic trials, three had checked whether the blinding held, and it hadn’t held in any of them; not one of forty-three studies had measured what participants expected before they began. When people know what they’ve been given, and hope it will work, the effects “are likely over-estimated.”

There’s a fair answer to that, and the section owes it. When researchers went back to the escitalopram trial and looked at what people had expected, expectation predicted how well they did on the antidepressant, but not on psilocybin. Psychedelic therapy, they concluded, “may be less vulnerable to expectancy biases than previously suspected.” One analysis. But it’s the right kind of evidence.

Two more losses belong on the record. Microdosing, taking tiny amounts you can barely feel, became a cultural phenomenon on the strength of personal stories. In 2021, a clever study had 191 people blind themselves: they mixed their real microdoses with placebo capsules in envelopes they couldn’t tell apart, and took them without knowing which was which. Both groups improved, about equally. The anecdotes, the authors concluded, could be explained by the placebo effect. And in 2024, the FDA rejected MDMA-assisted therapy for post-traumatic stress after its advisers voted 10 to 1 that the benefits didn’t outweigh the risks. Nearly every participant had known they’d had MDMA, safety data were missing, and a journal retracted three papers over misconduct at one trial site.

The harms deserve the same plain telling. In a large survey of people who’d had a difficult psilocybin experience, about one in ten said they’d put themselves or someone else at risk of harm during it; a small minority sought medical help or later sought treatment for lasting symptoms. Most of the same people also said they’d benefited. Big population surveys have found no link between lifetime psychedelic use and mental illness, and some have found less distress. Those are correlations among people who chose to use, not proof of safety either way.

As I write this, psilocybin is not an approved medicine anywhere in the United States. The company furthest along expects to finish its application this year.

So the medicine is real, and smaller than it first looked. That’s what twenty years of careful work has bought. Now: why does it work at all?

III.What the Evidence Explains

This is where the story gets stranger, and closer to what I know from the inside.

The lock. The key the mushroom made fits one lock above all: a serotonin receptor called 5-HT2A. In 2017, Katrin Preller and her colleagues in Zurich showed how much depends on it. They gave volunteers LSD, which works on the same receptor, and on another day gave them LSD along with a drug that blocks it. With the lock blocked, the whole experience simply didn’t happen: “general subjective LSD effects were fully blocked.” The visions, the dissolving, the strangeness, all of it, hinge on one kind of molecule fitting one kind of lock.

Meaning, on a switch. That same study did something I find almost unbearably interesting. Before the sessions, each volunteer had sorted pieces of music into ones that meant something to them and ones that didn’t. Under LSD, the music they’d called meaningless became more meaningful to them. Block the receptor, and that went away too. The last Inquiry on this site was about felt meaning: the sense that something matters, which arrives before you can say why. Here it is, turned on and off with a switch.

The music. And that brings me to the finding that matters most to me. The Hopkins sessions run to a playlist of nearly eight hours, most of it classical, shaped like the arc of the journey itself: onset, ascent, peak, and a final section its designer, William Richards, calls “welcome back to Earth.” The last songs on the 2008 version are “Here Comes the Sun” and “What a Wonderful World.” Richards describes the whole thing as “a nonverbal support system, sort of like the net for a trapeze artist.”

In 2018, researchers in London asked patients from a psilocybin depression trial about their music. They found that “the nature of the music experience was significantly predictive of reductions in depression 1 week after psilocybin, whereas general drug intensity was not.” They titled their paper “The hidden therapist.” It was a small study, nineteen people, and it measured a correlation, not a cause. But sit with what it says. In a field arguing over whether the drug or the experience does the healing, the quality of the music predicted who got better, and the strength of the drug didn’t. (It doesn’t have to be classical, either. A small 2021 study found no advantage for Beethoven over a playlist of gongs and bells.)

The senses crossing. Many people describe hearing music as colour or weight under psychedelics, as I do. It’s real, and common: in pooled studies, sound-to-sight crossings were the most often reported kind. But it isn’t the lifelong synesthesia some people are born with. When researchers tested it properly, the crossings didn’t hold steady from one moment to the next, the way true synesthesia does. The senses cross for the night, and then they let go.

The brain, coming apart. For years the popular story was that psychedelics switch off the default mode network, the part of the brain most active when we’re absorbed in ourselves. An influential 2012 study did find less activity there. The truth has turned out to be more interesting. In 2024 a team at Washington University scanned the same handful of people, seven of them, about eighteen times each, before, during and after psilocybin. They found that psilocybin “massively disrupted functional connectivity”: the brain’s usual patterns of which regions talk to which came apart, more than three times as much as with a stimulant, most of all in that self-absorbed network. Some of the changes lasted three weeks. The leading theory, called REBUS, says psychedelics “relax the precision of high-level priors”: they loosen the brain’s grip on its own expectations about how the world is. It’s a hypothesis, and a beautiful one. It isn’t proven.

Two roads. Here’s a finding I didn’t expect, and it describes something I’ve lived. When researchers asked what predicts feeling better after a session, they found two routes, partly separate. One runs through insight: seeing your own patterns, facing the things you’ve avoided. The other runs through something like connection, the feeling of being “part of the world instead of separate from it.” In a 2022 study, insight carried most of the benefit of emotional breakthroughs, but very little of the benefit of mystical experience. One patient in a London trial put the second road in a sentence: “We are all interconnected, it’s like a miracle!”

Usually I come back from a journey with insight that takes days to unpack. The last time, in October, I didn’t. It was a night of reconnection, and it was enough. The research says that’s not a failed journey. It’s the other road.

The feeling of truth. And here is the warning that comes with all of it. The last Inquiry described experiments in which a sudden flash of insight made an unrelated statement, even a false one, feel truer. In 2024, a group that included the scientist who ran those experiments proposed that psychedelics “can, in some cases, lead to false insights and thus false beliefs.” It’s a theory, not yet a finding. But a 2021 study did find that people who attended psychedelic ceremonies came away believing less in a purely material universe and more in a world where mind runs through everything, and kept believing it for months. In a controlled trial the difference wasn’t significant. Either way, those shifts are facts about the people. They aren’t facts about the universe.

Is the trip necessary? All of this comes to a head in one argument, and it’s the question this whole piece is asking. In 2021 a journal printed two papers side by side, with titles that contradict each other word for word. The chemist David Olson’s was called “The Subjective Effects of Psychedelics May Not Be Necessary for Their Enduring Therapeutic Effects.” David Yaden and Roland Griffiths’s was called “The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects.”

Olson’s case is that the link between mystical experience and recovery is a correlation, and that these drugs also make brain cells grow new connections, which might do the healing by themselves. His lab built a related molecule that doesn’t produce the experience, and in rats and mice it still had antidepressant-like effects. If that holds in people, you could have the medicine without the journey. Yaden and Griffiths’s case is that the experience predicts the benefit in trial after trial, that people rank it among the most meaningful events of their lives, and that the brain changes are “likely necessary but not sufficient.”

The decisive experiment would be simple to describe and hard to run: give people the drug with the experience blocked, and see whether the benefit survives. As far as I can find, no one has done it in humans. The question at the centre of this piece is still open.

IV.What Remains

So the question isn’t whether psychedelics do something real. They do. It’s whether they do what I said they do.

Here is my thesis at full strength. The experience is the point. What you meet in that state is reality with the veil lifted: unity known rather than believed, guidance from something that answers. That encounter is what heals, which is why the people with the deepest experiences tend to get the most benefit. And that’s why these plants have been treated as sacred, and feared, for as long as there are records.

Now the case against, and it’s strong.

The healing is real, but smaller than I believed. The miracle numbers came from small trials where nearly everyone knew what they’d taken. Larger, more careful trials show a modest benefit for depression, one that may fade.

The experience may not be what heals. It travels with the benefit, reliably. Whether it causes the benefit is exactly what serious people are fighting over, and the experiment that would settle it hasn’t been done.

And “more real” is a report, not a measurement. When 81 percent of people say an encounter was more real than ordinary life, that’s an important fact about the experience. It isn’t evidence that the encounter was more real. James chose his word carefully: these states seem to be states of knowledge. And the drug that produces the feeling of revelation may be able to produce the feeling of truth on its own.

I have my own test case for that. My strongest more-real-than-real experience came on the first psychedelic I ever took, and it wasn’t a mushroom. It was salvia, a sage the Mazatec of Oaxaca hold sacred. I went and lived another life. It was as real as this one, if not more. One day in that life I was walking down a street and came across a street vendor, and I saw a pair of red slippers poking out from under the table, and the sight of them told me it was about to end. Then the universe swallowed me up. It sent me through a series of tubes whose walls were faces, and the faces were giving me messages, until the walls of the tube morphed back into the room I’d taken it in. Then I had a second trip, and it was the same experience, except that this time the slippers were poking out from under a curtain in a bazaar.

Salvia matters to that question because it isn’t a cousin of psilocybin. Its active compound, salvinorin A, doesn’t touch the serotonin lock at all. When chemists finally worked out what it does, in 2002, they found it “had no actions at the 5-HT(2A) serotonin receptor,” the lock every classic psychedelic fits; it works on one of the brain’s opioid receptors instead. A different key, in a different door. And people still come back from it describing other places. In one laboratory study, a volunteer said, “It took me in a different place altogether, some sort of carnival tent,” and participants “reported disturbed reality monitoring.” It isn’t only drugs, either. In a 2019 survey of people who had encountered something they called God, those who’d had the experience on a psychedelic and those who’d had it without one “provided relatively high similar ratings that the experience was more real than everyday normal reality.”

So I reached my verdict through a different key, and people reach a similar one with no key at all. That cuts both ways, and I want to be fair to both. It could mean the feeling of realness is something the brain can be made to switch on from many directions, a stamp it presses onto whatever is in front of it, which would make the stamp hard to trust. Or it could mean that many doors open onto the same room. No study has yet compared how real these states feel across different drugs, so the question stays open.

McKenna, tested. The man this site is named for made claims that could be checked, and The Edge has to report how they fared. His “Timewave Zero” predicted that history would reach a point of infinite novelty on 21 December 2012, a date he reportedly adopted after learning of a Maya calendar correlation, from a calculation a mathematician later showed depended on an unexplained step in the software. The date came and went. His “Stoned Ape” theory, as he wrote it in 1992, said low doses of psilocybin had sharpened our ancestors’ eyesight and helped them hunt. The study he based that on, by Roland Fischer and colleagues in 1970, didn’t measure eyesight at all; it measured how people perceived the space around them, at a moderate dose, and Fischer read the change as the drug interfering with perception. Even sympathetic scientists now call “a simplistic version of McKenna’s account” “most certainly false.”

But I love the Stoned Ape, and I think its best version is better than McKenna’s. Forget the eyesight. Picture instead the plainest version of the story. Our ancestors followed the herds. The herds left dung. The dung grew mushrooms, and some of those mushrooms made psilocybin. People who ate nearly everything they found would have eaten those too, at least sometimes. What that did to the human mind is the open question.

The evidence has moved toward that story this year. In March, a team of mycologists described a new mushroom from Zimbabwe and southern Africa, the closest wild relative of Psilocybe cubensis, the psilocybin mushroom most people know. It grows almost only on the dung of grazing animals. By their estimate, the two split apart about a million and a half years ago, possibly alongside the great herds of the East African grasslands, and the authors note, as a speculation, that Homo erectus was spreading along those same herd routes at the time. We know Neanderthals ate mushrooms, and fungal remains, possibly mushrooms, have turned up in the teeth of our own ancestors from about eighteen thousand years ago. Chimpanzees in the wild drink fermented palm sap. In Lesotho, healers have been recorded using a native psilocybin mushroom.

None of that shows that early humans ate psilocybin, let alone that it changed them. There’s no direct evidence of psychedelic use in the Old Stone Age, and the origin of cubensis is still, in the researchers’ words, “heavily debated.” What would count is specific: traces of a psilocybin mushroom in the teeth or fossilized dung of an early human, or a signature in our genes that such exposure predicts and nothing else does. Until then, the encounter is plausible, and becoming more so. What it did to us is the residue.

The residue. Unexplained is not inexplicable, and a gap in one account is not evidence for any other. Here the gaps are clear. Much of the mechanism is known: a key and a lock, a brain whose patterns come apart for a while, an easing of its grip, and a room shaped by music. The healing is real and modest. What remains open is whether the experience itself is the medicine, and whether what people meet in that state is real.

McKenna saw the problem with that second question better than anyone. Asked in 1992 whether there was an alien intelligence in the mushroom, he said, “I don’t believe it as strongly as you imply,” and then: “One cannot find out whether or not there’s an extraterrestrial intelligence inside the mushroom unless one is willing to take the mushroom.”

That’s the instrument problem, stated by the man who named this site. The scanner can watch the brain change. The questionnaire can record that you called it more real. Neither can go where you went and check.

Roland Griffiths spent the last part of his career on these questions, giving psilocybin to people facing death and measuring what changed. In 2021 he was diagnosed with stage 4 colon cancer. He talked about it publicly before he died, in October 2023, and what he said wasn’t a finding. He said he was “truly grateful for the diagnosis,” that it had been “a call to celebration,” and he credited meditation with carrying him through. His last words in one interview were an invitation: “My parting invitation is to celebrate.” The man who measured the experience more carefully than anyone ended up standing at the same edge as his patients, with the instruments set down, and what he brought back from it was gratitude.

V.What the Traditions Said

None of what follows is evidence. The claim is about the persistence of a practice, not the truth of anyone’s metaphysics. The full history belongs to The Mycelium, where a new thread follows the sacred mushroom from ancient Greece to modern prohibition. What matters here is what the traditions knew about the experience itself, and about the room it needs.

They promised it was the most important thing a person could see. For centuries, initiates walked from Athens to Eleusis and drank a sacred barley drink, the kykeon, before seeing something they were forbidden to describe. Whether the drink held anything psychoactive is still argued. What was said about the experience isn’t. The Homeric Hymn to Demeter: “Happy is he among men upon earth who has seen these mysteries; but he who is uninitiate and who has no part in them, never has lot of like good things once he is dead …” And Sophocles: “Thrice blest are they / Who having seen these mystic rites shall pass / To Hades’ house.” That’s James’s noetic quality, two and a half thousand years early.

They had their skeptics, too. Plutarch, who preserved that line of Sophocles, preserved the reply. The philosopher Diogenes, hearing it, asked: “What! Do you mean to say that Pataecion, the robber, will have a better portion after death than Epaminondas, just because he is initiate?” Whether the vision makes you a better person was being argued two thousand years before anyone ran a trial.

They said it tasted of immortality. The Rig Veda, in Ralph Griffith’s 1896 translation: “We have drunk Soma and become immortal; we have attained the light, the Gods discovered.” No one knows for certain what plant soma was.

They said the plant speaks. For the Mazatec of Oaxaca, the mushrooms are ndi xi tjo, “the little ones that sprout,” or the saint children. The healer María Sabina said the mushrooms spoke through her in her chants; she saw herself as their interpreter. That’s the experience I described at the start, the plant that always feels like a response, named and honoured by a people who have lived with these mushrooms far longer than any laboratory.

And they built rooms for it. The Mysteries had priests, a sequence, and a long road to walk first. The Mazatec ceremony happens at night, led by a healer who knows the way. The Tibetan Bardo Thödol is read aloud to someone crossing between states, to tell them where they are; in 1964 Leary, Metzner and Alpert adapted it into a guide for psychedelic sessions. The clinical trials rediscovered the same thing and called it set and setting: a prepared mind, a safe room, a guide, and music. A living room with a couch. “Here Comes the Sun.” The traditions didn’t know about receptors. They knew what the trapeze artist needs underneath.

The persistence is the point. People in cultures that mostly never met each other described the same states, held them sacred, warned about them, and built the same kinds of rooms for them. The instruments have since measured some of what they described. They haven’t measured whether it’s true.

What this Inquiry does not establish

1. 01That psychedelics cure depression, addiction or anything else. Controlled benefits are real and smaller than early trials suggested. Durability beyond months is mostly uncontrolled.
2. 02That the trials were properly blind. Most weren’t, and expectations were rarely measured.
3. 03That the mystical experience causes the benefit. It travels with it. Whether the experience is necessary is an open fight.
4. 04That the brain “resets.” The network changes are real, depend on how they’re measured, and aren’t yet tied to outcomes.
5. 05That “more real than real” means more real. It records how the state is judged and what follows. These states “seem” to be knowledge. The same verdict comes from a drug that works on a different receptor (salvia), and from people who took nothing; no study has compared realness across drugs directly.
6. 06That drug-induced sense-crossing is synesthesia. It’s real experience, and it doesn’t pass synesthesia’s tests.
7. 07That early humans ate psilocybin mushrooms, or that it shaped the human mind. The encounter is plausible and becoming more so; there’s no direct evidence, and the effect is untested.
8. 08That these substances are safe for anyone, anywhere. Serious harm is rare in screened, supported settings and not rare outside them.
9. 09That this site recommends any of it. It describes. It doesn’t advise.

More Real Than RealThe Edgeimanantibody.com/edge/psychedelics

I said at the start that these experiences heal, that the plant answers, and that the veil lifts. The evidence gives me some of that, and takes some back. It gives me the healing, smaller than I’d hoped, and real. It gives me the music, which predicted who got better when the strength of the drug didn’t. It gives me the two roads, and a name for the October night when reconnection was enough. It takes back the miracle numbers, one larger trial at a time. And it won’t follow me past the veil, because no instrument can.

Somewhere tonight, a mushroom is pushing up through dung in a southern African grassland, making a molecule it has been making since the dinosaurs died, for reasons of its own. The molecule fits a lock in us that evolved for other reasons entirely. People have been walking through that accidental door since before there were records, and coming back to say the same things: that they were part of the world instead of separate from it, that it was more real than this, that it’s really hard to describe, you just know.

McKenna said you can’t find out what’s on the other side unless you’re willing to take the mushroom. More than thirty years later, the best research in the world has come to the same edge and stopped there, with the question open. The man who led that research ended his life inviting us to celebrate.

You sit with that. So do I.

This Inquiry is the empirical end of three pieces on the same territory. The contemplative end is the Signal reading Let It Happen, on Tame Impala and a long practice; the history is a new thread in The Mycelium, The Sacred Mushroom; a Collection draws the lines between them, and The Body Politic carries the politics in The Antibodies, Named and The Antibody Suppressed. The site’s founding teaching is The Antibody, from McKenna’s 1994 lecture Eros and the Eschaton. It continues the Edge’s earlier work: The Sea Is Not Full, and the second Inquiry, Carrying Over, on metaphor and felt meaning, whose false-insight findings return here. The charter for the whole section is Everything That I Am. Nothing here recommends that anyone take anything.